Sergey David
Lymphocytic vasculitis is one in all many skin conditions that square measure conjointly noted as body covering vasculitis. In white corpuscle vasculitis, white blood cells (lymphocytes) cause harm to blood vessels within the skin. This condition is assumed to be caused by a variety of things; however, the precise explanation for most cases isn't celebrated. This sickness will gift with a range of symptoms, reckoning on the scale, location, and severity of the affected space. In a very minority of patients, the body covering vasculitis may be a part of a lot of severe vasculitides poignant different organs within the body this can be called general vasculitis. Lymphocytic inflammation is assumed to be caused by variety of various factors, like infection, trauma, drug reaction, or AN underlying condition like inflammatory disease. As a result of this condition is rare and not nevertheless well understood, it's believed that a full list of doable causes has nevertheless to be assembled. Lymphocytic inflammation will cause variety of various symptoms. Hives, red or chromatic discoloured patches, a bump (nodule), or AN open sore (ulcer) have all been delineate as symptoms of this condition. The size, location, and severity of symptoms vary wide among affected people.
Tejas Thomas*, Dieter Götte, Bernhard Hellmich, Duvuru Geetha, Peter Antony Rutherford, Kumari Priyanka
Background: Glucocorticoids are cornerstone for treatment of anti-neutrophil cytoplasmic Antibody-Associated Vasculitis (AAV) but
their significant dose-dependent toxicity is a major concern in clinical practice. This systematic review aims to determine the frequency
and proportion of glucocorticoid-related adverse events in patients with AAV.
Method: A systematic literature search was performed in the Embase, Medline and PubMed databases with limitation on years of publication
between January 2000 and December 2020. Full text articles from randomized controlled trials, other interventional and observational
studies including data on the study design, population size, drugs administered and adverse events reported were considered for the
analyses. Studies focused exclusively on eosinophilic granulomatosis with polyangiitis were excluded. A regression model was run to
explore the relationship between mean doses of glucocorticoids, duration and reported adverse events. Furthermore, a correlation matrix
was generated to analyse the rate of incidence of adverse events.
Results: A total of 91 articles were reviewed. Most frequently reported serious adverse events included death (12%) and severe infections
(9%) while non-serious adverse events included infections (not specified) and leukocytopenia (approximately 14%each). Diabetes was
frequently reported according to the Vasculitis Damage Index components. Regression analysis revealed a significant association between
duration of glucocorticoid treatment and occurrence of infections and eye disorders (not specified, p<0.05). There was no significant
association between the mean glucocorticoid dose and occurrence of reported adverse events.
Conclusion: The increasing clinical burden of glucocorticoid-related adverse events in patients with AAV could be reduced by considering
advanced therapeutic strategies.
Suvesh Singh, Bhavya Swarnkar*, Neetu Bhari and Akash Deep Chandra
DOI: DOI: 10.37421/2471-9544.2022.8.154
According to World Health Organization (WHO), Dolutegravir-based regimen is considered as first-line therapy for PLHIV and strongly recommended for all adults and children at the 10th International AIDS Society Conference on HIV Science (IAS 2019) held in Mexico City. Dolutegravir (integrase inhibitor) is pharmacokinetically favorable with a single daily dose, fewer drug interactions, superior potency against HIV-1, and potency against efavirenz-resistant virus. In 2020, NACO announced the phase-wise replacement of TLE regimen to TLD regimen.
Cihan Uysal*, Tugba Yilmaz, Hafsa Kocyigit, Hulya Akgun and Murat Hayri Sipahioglu
DOI: DOI: 10.37421/2471-9544.2022.8.159
ANCA test has diagnostic significance on AAV. The Immunofluorescence Assay (IFA) usually has a perinuclear staining pattern (PANCA), and Enzyme-Linked Immuno Sorbent Assays (ELISA) detect antibodies to Myeloperoxidase (MPO-ANCA) in MPA. Kidney involvement is noted in approximately 80-100 percent of patients with MPA cases, and the clinic spectrum range from microscopic hematuria to severe kidney injury with dialysis requirement. Pulmonary involvement is noted in approximately 25-55 percent of patients with MPA. Several observations and presumptions have been noted about TIN accompanying crescentic glomerulonephritis. This diversity may be considered as only a simple histological elaboration. However, it is a significant clinical entity for guiding the treatment.
Chaïmaâ Zeroual*, Merieme Benzakour, Mina Moudatir, Khadija Echchilal, Leïla Barakat, Safaâ Mourabit and Hassan El Kabli
DOI: 10.37421/2471-9544.2024.10.260
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) encompasses a group of rare autoimmune diseases affecting small blood vessels, including granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, and microscopic polyangiitis. Diagnosing AAV relies on clinical, biological, radiological, and histological findings. Despite advancements in understanding and treating these conditions, challenges remain in accurate prognosis and therapy management. The Five-Factor Score and Birmingham Vasculitis Activity Score are used to evaluate disease severity and guide treatment decisions, yet these tools have limitations and may not fully capture disease complexity. Recent epidemiological studies have highlighted the geographic variability in AAV incidence and the role of ANCAs as diagnostic and prognostic markers. Treatment involves an initial remission induction phase followed by maintenance therapy, often corticosteroids and immunosuppressants like rituximab and cyclophosphamide. However, newer agents such as mepolizumab and avacopan show promise, particularly for specific AAV subtypes. Evaluating sequelae using indices like the Vasculitis Damage Index is critical, given the increased survival rates and focus on quality of life. While current treatment protocols aim to reduce relapse and manage complications, including infections and metabolic issues, there is a need for more tailored approaches. The revised Chapel Hill classification has improved disease definitions, but the absence of ANCAs sometimes complicates diagnosis. This review underscores the necessity for developing more refined prognostic and activity scores to enhance the clinical management of AAV and calls for ongoing research to optimize treatment strategies and outcomes for affected patients.
Journal of Vasculitis received 83 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 